Odne, a pioneering dental startup based in Dübendorf, Switzerland, has announced a successful Series A1 funding round, securing $5M (approximately €4.5M). The round was led by Revere Partners and NV Capital, with additional investments from several renowned funds including Dental Innovation Alliance (DIA), Plug&Play, Hatcher, Züricher Kantonalbank, as well as various family offices and angel investors. This new funding will support the upcoming market launch in the United States.
Dr. Andreas Schmocker, CEO & Co-Founder of Odne, emphasized the significance of the US market, which accounts for over 15 million root canal treatments annually, making it the largest market worldwide. “Currently, we are performing a Priority Access Program to deepen the use of our products with selected US key opinion leaders. At the annual meeting of the American Association of Endodontists (AAE) in April, in Los Angeles, we will introduce the Odne RPT workflow solution to the endodontic community,” Schmocker stated.
Advertisement
Addressing Root Canal Treatment Challenges
Root canal treatments, with over 60 million procedures conducted globally each year, have historically faced challenges including low success rates ranging from 46% to 91%. These issues result in significant healthcare costs. The Swiss Startup, founded in 2018 by Andreas Schmocker and Mark Bispinghoff, aims to revolutionize root canal treatments with its technology platform for Root Preservation Therapy (RPT).
Innovative Medical Devices
Odne’s RPT platform features three new medical devices designed for minimal invasive root canal cleaning and light-cured obturation:
- Odne Clean: The first hydro-dynamic cavitation device using saline as the main debridement medium.
- Odne Fill: An FDA-cleared highly flowable, light-cured obturation material.
- Odne Cure: A micro laser for light curing inside the root canal.
These devices are set to address the challenges of debridement and obturation in complex root canal morphologies, offering a safer and faster alternative to traditional methods.
Investor Confidence
Revere Partners, a venture capital fund globally focused on investing in oral health technology, expressed confidence in the startups potential to innovate within the oral health sector. Dr. Jeremy Krell, Managing Partner at Revere Partners, highlighted the significance of FDA clearance for Odne™Cure and Odne™Fill in 2023, stating, “The series A1 financing fuels the company’s US market launch to the endodontic community. Together with all investors, Revere Partners is proud to elevate the RPT workflow for the benefit of patients, endodontists, and the referring general dentists.”
With this latest funding, the startup is poised to make a significant impact on the dental industry, offering innovative solutions for root canal therapy that promise to improve patient outcomes and streamline the treatment process.
